In view of the frequent cases of corona virus, countries all over the world are paying more attention to vaccination. In many countries, the campaign to apply booster dose of corona virus has also started. Meanwhile, the US Centers for Disease Control and Prevention (CDC) has claimed that without the corona vaccine, the risk of dying from infection may be 10 times higher. After which the effort to get more and more people vaccinated in America has also been intensified.
US CDC also expressed concern
Three new studies by the US Centers for Disease Control and Prevention (CDC) emphasize the importance of COVID shots in preventing mortality, even amid concerns over reduced immunity in certain populations. The findings of these three studies are released in the CDC’s Morbidity and Mortality Weekly Report.
This study has shown that people who did not get the Kovid vaccine are 10 times more likely to die from the infection than those who did not get the vaccine. It is also learned that the currently available COVID-19 jabs provide strong protection against hospitalization and death to most people, even during delta surges. However, regardless of vaccination status, higher hospitalization and mortality are observed in older age groups.
Survey done in 13 states of America
For the study, CDC analyzed data on more than 600,000 COVID-19 cases, hospitalizations, and deaths for people 18 years of age and older reported from April 4 to July 17 in 13 states and cities. . The vaccine’s effectiveness against the infection fell by 90 percent, while the Delta outbreak had not peaked by that time.
Vaccines reducing hospitalization
The Washington Post reported that there was hardly any drop in effectiveness against hospitalization and death during the entire period. Mehul Suthar, a virologist at Emory University, said achieving 80 percent is still a very good number. These vaccines are still against a highly permeable variant. A second study showed that Moderna’s vaccine for COVID-19 is significantly more effective against the delta version of the SARS-Cov 2 virus than Pfizer or Johnson & Johnson. It suggested that Moderna was 95 percent effective at preventing hospitalization in adults 18 years of age and older, while Pfizer was 80 percent effective and Johnson & Johnson 60 percent effective.